References
- Clara JA, Sallman DA, Padron E. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Cancer Biol Med. 2016;13:360–372.
- National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER) cancer statistics review 1975-2010: Section 30 – Myelodysplastic syndromes (MDS), chronic myeloproliferative disorders (CMD), and chronic myelomonocytic leukemia (CMML). 2012 [cited 2017 Dec 21]. Available from: http://seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_30_mds.pdf.
- Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536–1542.
- List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549–557.
- Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. Jco. 2016;34:2988–2996.
- Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(1):60–87. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx
- Zeidan AM, Gore SD, McNally DL, et al. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer. 2013;119:3870–3878.
- Kim H, Lee JH, Lee WS, et al. Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome. Blood. 2015;126:1687.
- Zeidan AM, Al Ali NH, Padron E, et al. Lenalidomide treatment for lower risk nondeletion 5q myelodysplastic syndromes patients yields higher response rates when used before azacitidine. Clin Lymphoma Myeloma Leuk. 2015;15:705–710.
- Wade RL, Korytowsky B, Singh P, et al. The novel generation and validation of survival curves in oncology utilizing electronic medical records linked to point of service claims data. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) European Congress; 2017 November 4–8; Glasgow, Scotland, UK.
- Uno H, Cronin A, Wadleigh M, et al. Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS). Leuk Res. 2014;38:1420–1424.
- Carnahan RM. Mini-Sentinel’s systematic reviews of validated methods for identifying health outcomes using administrative data: summary of findings and suggestions for future research. Pharmacoepidemiol Drug Saf. 2012;21:90–99.